DOI: 10.1111/idv.14295

REVIEW ARTICLE

Consensus statement on prevention and management of adverse effects following rejuvenation procedures with hyaluronic acid-based fillers

W.G. Philipp-Dormston, ^{1,*} D. Bergfeld, ² B.M. Sommer, ² G. Sattler, ³ S. Cotofana, ^{4,5} P. Snozzi, ⁶ U. Wollina, ⁷ K.P.J. Hoffmann, ⁸ C. Salavastru, ⁹ K. Fritz^{9,10}

Abstract

Facial fillers play an important role in the correction of facial changes associated with ageing. They offer quick treatments in the outpatient setting with minimal subsequent downtime that provide predictable, natural-looking, long-lasting results. Adverse reactions after hyaluronic acid injections tend to be mild or moderate and rather temporary. However, as with all injected or implanted biomaterials, severe adverse events can occur and patients must be fully informed of potential risks prior to undergoing treatment. A panel of experts from Germany (D), Austria (A) and Switzerland (CH) developed recommendations, and this study provides the 'DACH Consensus Recommendations' from this group specifically on the use of hyaluronic acid fillers. The aim is to help clinicians recognize potential risks and to provide guidance on how best to treat adverse events if they arise. Contraindications to hyaluronic acid fillers are also detailed, and ways to prevent adverse events occurring are discussed. Hyaluronic acid-based products are claimed to be very close to an ideal tissue augmentation agent; nevertheless, profound medical, anatomical and product knowledge are of paramount importance to minimize the occurrence of adverse reactions.

Received: 6 October 2016; Accepted: 10 April 2017

Conflicts of interests

Dr Philipp-Dormston has been study investigator and member of the scientific advisory boards of Allergan, Biofrontera, Galderma, L'Oreal, Leo and Merz and received honoraria and scientific support by these companies. There is no conflict of interest or influence regarding this publication by any means.

Dr. Snozzi has been a member of the scientific advisory board of Allergan and reports personal fees and non-financial support from Allergan, Merz and Galderma outside of this submitted work.

Dr. Sommer reports personal fees from Pharm-Allergan, non-financial support from Galderma, and personal fees from Merz Pharmaceuticals outside of the submitted work.

Dr. Hoffmann worked as a consultant running studies and workshops for Allergan and Galderma.

Dr Wollina, Dr Bergfeld, Dr Sattler, Dr Salavastru, Dr Fritz and Dr Cotofana have no conflict of interests relevant to this manuscript to declare.

Sources of funding

The organization of the consensus conference and scientific funding was supported by Pharm-Allergan GmbH, Frankfurt, Germany, and Galderma Laboratorium GmbH, Düsseldorf, Germany.

¹Hautzentrum Köln (Cologne Dermatology), Köln, Germany

²Sommerclinics, Frankfurt am Main, Germany

³Rosenparkklinik, Darmstadt, Germany

⁴Institute of Anatomy, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria

⁵Department of Anatomy, Ross University School of Medicine, Roseau, Commonwealth of Dominica, West Indies

⁶Smoothline, Zürich, Switzerland

⁷Academic Teaching Hospital of Technical University of Dresden, Dresden, Germany

⁸St. Josef-Hospital Bochum, Abteilung für Ästhetisch Operative Medizin und Kosmetische Dermatologie, Bochum, Germany

⁹Department of Paediatric Dermatology, Colentina Clinica Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

¹⁰Dermatology and Lasercenters, Landau, Germany

^{*}Correspondence: W.G. Philipp-Dormston. E-mail: mail@haut-zentrum.com